PNAS: New research suggests it is possible to develop a universal new coronavirus vaccine

In a new study, researchers from the Walter Reed Army Research Institute in the United States analyzed gene sequences from more than 27,000 patients infected with the new coronavirus that causes COVID-19 and found that the virus had the lowest mutation since December 2019, suggesting that a vaccine would be sufficient to fight global infections. The findings, recently published in the journal PNAS, are titled "A SARS-CoV-2 vaccine candidate would likely match all currently agency. The paper is co-authored by Morgane Rolland, Director of Viral Genetics and Systems Serology at the Walter Reed Army Institute, and Dr. Kayvon Modjarrad, Director of the Emerging Infectious Diseases Program at the Walter Reed Army Institute.To show the diversity of coronavirus SARS-CoV-2 since the pandemic began, they compared 18,514 individual viral genome sequences sampled from patients in 84 countries and scanned for their mutations. The results show that genetic differentiation estimates are low after the initial outbreak, and suggest that so far the evolution of the SARS-CoV-2 genome has been mostly random rather than adapted to the human hosts it encountered."As with other reports, we have noted a rapid increase in the frequency of D614G mutations in SARS-CoV-2 hedgehog proteins since the outbreak began, but we have not been able to link this mutation to specific adaptation forces," Rolland said. As the virus replicates and spreads through populations, we want to see mutations that can be quickly fixed in an epidemic through random opportunities. Rolland noted that linking genotypes to esotypes is complex and more research is needed to fully understand the functional consequences of D614G mutations in SARS-CoV-2 hedgehog proteins.Given the low degree of genetic variation, a promising candidate vaccine is likely to have the same effect on all currently circulating COVID-19 coronavirus strains."Virus diversity challenges vaccine development for other viruses, such as HIV, influenza and dengue, but global samples show that SARS-CoV-2 is less diverse than these viruses," Rolland said. Therefore, we can be cautiously optimistic that viral diversity should not be an obstacle to the development of a broad protective vaccine against COVID-19 infection. Modjarradled the COVID-19 response at the Walter Reed Army Institute, including the development of a vaccine against COVID-19. The candidate vaccine from the Walter Reed Army Institute is based on the Spike Ferritin Nanoparticle platform and is expected to be tested in humans by 2021. The vaccine is used in conjunction with a special adjunction --- Army Liposome ---, also developed by the Walter Reed Army Research Institute, to further enhance the immune response."Scientists are working to accelerate the development of a COVID-19 vaccine that is safe and effective around the world now and in the next few years," Modjarrad said. These data are critical to providing information for collective efforts in this area to obtain a vaccine that can be rapidly expanded and universally applicable to all populations.added, "Based on the Walter Reed Army Institute's long experience in developing vaccines for other viruses, as well as recent work on coronavirus, we have been able to move quickly to accelerate research to combat this epidemic, which threatens global health and military readiness." "Research in Theory of Humane Technology usually focuses on HIV genetics, and in the current global health emergency, she has turned her attention to COVID-19. "When we focus on understanding everything about this coronavirus, it's critical that people in all fields work together," she said. Teamwork will be crucial to stopping the spread of the epidemic. "(Bio Valley) Bioon.com)